Investor & News

Investors & News

Corporate Profile

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using the company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.

The company’s first compound, zorevunersen (STK-001) is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease.

The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the company’s belief in the broad potential for its proprietary approach.

Press Releases

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

June 3, 2024

BEDFORD, Mass. --(BUSINESS WIRE)--Jun. 3, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 17, 2024

BEDFORD, Mass. --(BUSINESS WIRE)--May 17, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

May 6, 2024

– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential ...

Corporate Presentation

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.

Investor Events

Investor Inquiries